In the European Parliament: what the EU Biotech Act should do for rare diseases


October 2026

At the Expert Dialogue on the EU Biotech Act in the European Parliament.


In October Sebastian was invited to speak at the European Parliament’s Expert Dialogue on the EU Biotech Act, hosted by MEP Stine Bosse together with MEP Vytenis Andriukaitis. Cecilie and Walther came along.

His message: for many rare diseases, science is no longer the bottleneck. Capital and regulation are.

He asked that the Act do three things:

Make sure its investment pilot reaches the earliest stage, where new treatments start.
Let developers build on platform technologies and alternative pathways, to cut development costs and reach patients faster.
Give rare disease trials one European process.

“Patients should not wait for the slowest procedure in the slowest country.”


Why does a patient foundation spend time on legislation? Because the rules decide whether a therapy for a small group of patients can be developed at all.

All stories